Dr. Drew W. Rasco is the Associate Director of Clinical Research at START. He is board-certified in both Hematology and Oncology. He completed medical school in 2003 at the University of Texas Health Sciences Center in San Antonio, TX. He completed his residency in Internal Medicine at the Emory University School of Medicine in Atlanta, GA. He followed this with fellowships in Hematology and Oncology at the University of Texas Southwestern Medical Center in Dallas, TX.

Dr. Rasco’s major interest is in the development of new anticancer agents, with a special interest in malignancies of the gastrointestinal tract and lungs.

Dr. Rasco is a member of the American Society of Clinical Oncology (ASCO). He was a recipient of the Resident Achievement Award from Emory University. He and his partners at START have led an extensive number of phase 1 clinical trials, including those that eventually led to the FDA approvals of pembrolizumab, cemiplimab, abemaciclib, copanlisib, and others.  Most recently, he served as the principal investigator for the combination of lenvatinib and pembrolizumab, which received FDA approval for endometrial (uterine) cancer in 2019.